Drugs / BHV-8000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06976268 | May 2025 → Aug 2027 expected | Parkinson disease | Biohaven Therapeutics Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BHV-8000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06976268 ↗ |
| Route | Oral | “taken orally” NCT06976268 ↗ |